ANTEPAR Drug Patent Profile
✉ Email this page to a colleague
When do Antepar patents expire, and when can generic versions of Antepar launch?
Antepar is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in ANTEPAR is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
Summary for ANTEPAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 56 |
Patent Applications: | 103 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANTEPAR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ANTEPAR
US Patents and Regulatory Information for ANTEPAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | ANTEPAR | piperazine citrate | SYRUP;ORAL | 009102-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | ANTEPAR | piperazine citrate | TABLET;ORAL | 009102-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |